TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39166327
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg once daily)
Study: 35065057
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (240 mg every 2 weeks for up to three doses before surgery, then 480 mg every 4 weeks for 2 years)
Study: 35065057
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (240 mg nivolumab every 2 weeks plus 1 mg/kg ipilimumab concurrently with the first preoperative dose, then 480 mg nivolumab every 4 weeks for 2 years plus 1 mg/kg ipilimumab every 6 weeks for up to four cycles)
Study: 32827517
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ropinirole
Study: 34521264
Drug: 100,000 IUs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 IUs of ergocalciferol monthly after bariatric surgery
Study: 34521264
Drug: Standard level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard level vitamin D supplement after bariatric surgery
Study: 34192426
Drug: NVX-CoV2373 vaccine
Normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 vaccine (5-μg doses, 2 doses administered 21 days apart)
Study: 34192426
Drug: NVX-CoV2373 vaccine
Normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 vaccine and placebo
Study: 32919280
Drug: CER-001 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-001 (8 mg/kg, intravenous infusions, 9 weekly infusions followed by infusions every two weeks)
Study: 32414130
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels < 30 ng/mL in AS patients
Study: 32414130
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels < 20 ng/mL in AS patients
Study: 32414130
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels < 10 ng/mL in AS patients
Study: 32414130
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels < 30 ng/mL in male AS patients
Study: 32414130
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels < 20 ng/mL in male AS patients
Study: 32414130
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels < 10 ng/mL in male AS patients
Study: 32374239
Drug: Systemic+short infusion
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic+short infusion TXA
Study: 32374239
Drug: Systemic+long infusion
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic+long infusion TXA
Study: 32374239
Drug: Systemic+oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic+oral TXA
Study: 34582653
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and Bisoprolol
Study: 32312606
Drug: Classification-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classification-specific treatment (exercise to control or prevent lumbopelvic motion during lower-extremity movement)
Study: 33740977
Drug: Opioid analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesia alone (standard treatment)
Study: 33740977
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia (Pregabalin, Acetaminophen, Naproxen, and opioids if required)
Study: 33879005
Drug: Treatment-resistant depression
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant depression (TRD)
Study: 33834177
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (isoniazid for all 14 days, n=18)
Study: 35576286
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anaesthesia with 12 ml of 0.25% bupivacaine and 1% lignocaine plain (Group T)
Study: 33940347
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks or 400 mg every 6 weeks by intravenous infusion)
Study: 33940347
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC: FOLFOX6/FOLFIRI alone or in combination with bevacizumab/cetuximab)
Study: 34082792
Drug: Ayurveda interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ayurveda interventions including Agastya Haritaki 6g and Ashwagandha tablet 500mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days.
Study: 36127739
Drug: Inhaled aviptadil
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled aviptadil (67 μg, three times a day for 10 days)
Study: 36425919
Drug: Pre-emptive ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive ultrasound-guided single-shot lateral sciatic nerve block with 20 ml of 0.75% ropivacaine
Study: 32763109
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg, paclitaxel 175 mg/m(2), and carboplatin AUC 5; median bevacizumab duration was 6.7 months; 57% received maintenance bevacizumab.
Study: 32150521
Drug: Restrictive 72-hour
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive 72-hour short-term antibiotic strategy
Study: 32150521
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic usage
Study: 32150521
Drug: Restrictive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive antibiotic strategy
Study: 35575766
Drug: Propofol‐remifentanil total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol‐remifentanil total intravenous anesthesia alone
Study: 35587574
Drug: ArtemiC oral
Normalized name: acetaminophen / oxycodone hydrochloride Extended Release Oral Tablet [Xartemis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ArtemiC oral spray, twice daily on Days 1 and 2, beside standard care
Study: 35587574
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral spray, twice daily on Days 1 and 2, beside standard care
Study: 34028012
Drug: Transnasal Humidified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE), FIO2 1.0, 70 L min−1 during apnoea
Study: 32503652
Drug: Dill powder
Normalized name: Dill
DrugBank: Dill (DB10673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dill powder supplementation (3 g/day)
Study: 36130734
Drug: Opioid antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Opioid antagonists
Study: 34049922
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg weekly
Study: 33446039
Drug: 3D‐MOT training
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D‐MOT training (twice per week for 12 weeks)
Study: 35949922
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg in 0.4 mL), four injections every 3 months
Study: 35949922
Drug: Saline (placebo),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (placebo), four injections every 3 months
Study: 39478521
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine infusion
Study: 33570701
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 50,000 IU PO weekly for 12 weeks
Study: 33270145
Drug: Juul EU
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juul EU (20 mg/ml)
Study: 33270145
Drug: Juul US
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juul US (59 mg/ml)
Study: 38278871
Drug: Ivosidenib 500
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib 500 mg once daily
Study: 34050857
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy for Suicide Prevention + treatment as usual (CTSP + TAU) (N=75)
Study: 34050857
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual (TAU) alone (N=75)
Study: 34968972
Drug: Sequential Multiple-Assignment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Multiple-Assignment Randomized Trial (SMART)
Study: 33986878
Drug: Booklet +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booklet + Oral Presentation
Study: 33986878
Drug: Booklet +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booklet + Oral Presentation + Clinical Teaching
Study: 33021606
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (15 mg twice daily for 2 weeks, followed by clarithromycin [500 mg daily] for 12 weeks)
Study: 33021606
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (15 mg twice daily for 2 weeks, followed by placebo for 12 weeks)
Study: 32730905
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg twice daily) plus aspirin (100 mg once daily) for 12 months
Study: 32730905
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg daily) for at least 3 months on a background of aspirin (100 mg once daily) for 12 months
Study: 34212177
Drug: Provider-targeted intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-targeted intervention including education on appropriate RTD prescribing and monthly peer comparison feedback.
Study: 32541462
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal patch (BTP) 10 mg for 14 days
Study: 32541462
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic regimen (IV paracetamol 1 mg every 8 hours alternating with parenteral tramadol 50 mg every 8 hours for the first 2 postoperative days, followed by oral administration of the same drug until the end of 2 weeks)
Study: 35305278
Drug: HEAT (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEAT (5 × 50 min weekly heat suit training sessions)
Study: 35238765
Drug: MIV-711 100
Normalized name: MIV-711
DrugBank: MIV-711 (DB15599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV-711 100 mg
Study: 35238765
Drug: MIV-711 200
Normalized name: MIV-711
DrugBank: MIV-711 (DB15599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIV-711 200 mg
Study: 32434362
Drug: Plum blossom
Normalized name: OCTISALATE 4.7 g in 100 g / ZINC OXIDE 15 g in 100 g TOPICAL LIPSTICK [TATCHA THE KISSU LIP TINT SPF 25 PLUM BLOSSOM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plum blossom needle acupuncture with qi-invigorating superficies-consolidating therapy
Study: 34392492
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (Gr.A)
Study: 33481251
Drug: Acute intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intravenous glucose-induced hyperglycaemia
Study: 34751757
Drug: Early surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surgical treatment within 24 hours after admission
Study: 34751757
Drug: Delayed surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed surgical treatment after at least 2 weeks of conservative treatment
Study: 33038271
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg alcohol dose
Study: 34290294
Drug: FLNA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLNA and CLU combination
Study: 34290294
Drug: FLNA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLNA and CLU combination (with hepatic fibrosis and non-alcoholic fatty liver as control)
Study: 35502002
Drug: Cognitive-reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-reminiscence therapy (CRT)
Study: 34590570
Drug: Senling Baizhu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senling Baizhu san (SLBZS) 100 mL, twice a day, for 12 weeks
Study: 32419303
Drug: Exercise combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise combined with education and manual therapy
Study: 33973923
Drug: Bup/Nal treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bup/Nal treatment for 12 weeks
Study: 33973923
Drug: Detox treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detox treatment for up to 2 weeks
Study: 33341406
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg CaEDTA in Tris‐buffered saline nebulised with 250 mg tobramycin
Study: 33341406
Drug: Placebo (Tris‐buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Tris‐buffered saline) nebulised with 250 mg tobramycin
Study: 35035537
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with ‘step-up’ DMARD therapy
Study: 35035537
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy with NSAIDs and local corticosteroid injections
Study: 32022863
Drug: Once-weekly placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly placebo
Study: 35915506
Drug: Extended-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release guanfacine (GXR)
Study: 615709281
Drug: Cannabis (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis (54 mg) administered orally
Study: 615709281
Drug: THC (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (3 and 10 mg/kg) administered to mice
Study: 34569871
Drug: Picture-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picture-based medication calendar
Study: 34165835
Drug: Four implants
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four implants in maxillary overdentures
Study: 34165835
Drug: Denture supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denture supported by four implants
Study: 34165835
Drug: Two implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implants in mandibular overdentures
Study: 34726230
Drug: Recombinant hGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hGH treatment (various doses)
Study: 34464358
Drug: High-dose convalescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose convalescent plasma (3 units) plus standard treatment
Study: 38066597
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment alone)
Study: 34464358
Drug: Higher cumulative
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cumulative amount of neutralizing antibodies plus standard treatment
Study: 34314402
Drug: Volar plate
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volar plate fixation (operative treatment)
Study: 34314402
Drug: Cast immobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cast immobilization (nonoperative treatment)
Study: 35546018
Drug: ICS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS treatment
Study: 33834608
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg L-Cystine and 250 mg L-Glutathione
Study: 33834608
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg reduced L-Glutathione
Study: 33834608
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg L-Cystine
Study: 34156693
Drug: RefluG™ (galactomannan-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: RefluG™ (galactomannan-based formulation), one sachet three times per day for 14 days
Study: 32086918
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides Farinae
Study: 33767795
Drug: 1% Satureja
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Satureja khuzestanica vaginal cream
Study: 33767795
Drug: 1% clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clotrimazole vaginal cream
Study: 37679711
Drug: ACAT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAT program and treatment‐as‐usual
Study: 37679711
Drug: treatment‐as‐usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment‐as‐usual
Study: 33789610
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (200 ml IV at 100 ml/h)
Study: 33789610
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 ml IV)
Study: 32867282
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of omega‐3 long chain polyunsaturated fatty acids (n‐3 LCPUFA) and multivitamin supplements
Study: 36239645
Drug: Thrombectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombectomy plus medical therapy
Study: 36239645
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy only (control)
Study: 32051083
Drug: Concerta treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerta treatment
Study: 32051083
Drug: Strattera treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strattera treatment
Study: 37660037
Drug: Pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg three times daily and amoxicillin/clavulanic acid 500/125 mg three times daily for 10 days
Study: 37660037
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 500 mg twice daily or oral trimethoprim–sulfamethoxazole 800 mg/160 mg twice daily or intravenous ertapenem 1 g once daily for 7–10 days
Study: 32031091
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg of dexmedetomidine in 0.3 ml of normal saline (Group D)
Study: 32031091
Drug: 0.3 ml
Normalized name: ethanol 0.3 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml of normal saline alone (Group S)
Study: 32212997
Drug: Laparoscopic-Assisted Extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic-Assisted Extracorporeal Ureteral Tapering Repair (EUTR)
Study: 32772395
Drug: Single-implant (G-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-implant (G-I)
Study: 32772395
Drug: Two-implant overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant overdentures (G-II)
Study: 32772395
Drug: Fixed 4-implant
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 4-implant complete denture (G-III)
Study: 35713772
Drug: Osimertinib adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib adjuvant therapy
Study: 32605447
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg cannabidiol
Study: 32605447
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cannabidiol
Study: 35241098
Drug: CoQ10 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (120 mg)
Study: 34247263
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5 mg intravenous infusion once yearly for 2 years
Study: 32076362
Drug: Moderation-based alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderation-based alcohol treatment with naltrexone and Modified Behavioral Self-Control Training
Study: 35180190
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester (KME; 0.5 g·kg‐1)
Study: 34261858
Drug: Eflornithine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine (750 mg) + Sulindac (150 mg)
Study: 34261858
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg)
Study: 34261858
Drug: Eflornithine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine (750 mg)
Study: 32915063
Drug: Antibacterial envelope
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial envelope (TYRX) adjunctive to standard-of-care infection prevention
Study: 35501751
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (15 mg/kg before incision and 1 mg/kg/hour during operation)
Study: 35501751
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo: 0.9% sodium chloride solution)
Study: 34555333
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg every 21 days for 16 cycles or 1 year)
Study: 34909951
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg/day (Group O)
Study: 34909951
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg/day (Group M)
Study: 33517316
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with anthracycline followed by paclitaxel, RDI ≥85%
Study: 33517316
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with anthracycline followed by paclitaxel, RDI <85%
Study: 33071237
Drug: PRT +
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PRT + metformin (metPRT)